Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rodent bispecific antibody neutralizing DKK1 and sclerostin
- Development stage
- Preclinical
- Lead developer
- Angitia Biopharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Rodent bispecific antibody neutralizing DKK1 and sclerostin (rbsAb) is a preclinical surrogate bispecific antibody developed by Angitia Biopharmaceuticals. It simultaneously targets and neutralizes Dickkopf-1 (DKK1) and sclerostin, two key negative regulators of the Wnt/β-catenin signaling pathway that suppress bone formation. By dual-targeting these proteins, rbsAb prevents the compensatory upregulation of one pathway when the other is inhibited, leading to a more robust anabolic bone response. In preclinical models, rbsAb has demonstrated efficacy in reducing spontaneous fractures, increasing bone mass, and improving bone structure and strength in mouse models of osteogenesis imperfecta (OI) and chronic kidney disease (CKD).
- Other names
- rodent bispecific antibody neutralizing both Dickkopf-1 and Sclerostinsclerostin/DKK1 rodent bispecific antibody
02
Targets
DKK1 (Dickkopf-related protein 1)SOST (Sclerostin)
Beyond the preview
Go deeper on rodent bispecific antibody neutralizing DKK1 and sclerostin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rodent bispecific antibody neutralizing DKK1 and sclerostin.